Mepivicaine en es it fr

Mepivicaine Brand names, Mepivicaine Analogs

Mepivicaine Brand Names Mixture

  • No information avaliable

Mepivicaine Chemical_Formula


Mepivicaine RX_link

Mepivicaine fda sheet

Mepivicaine FDA

Mepivicaine msds (material safety sheet)

Mepivicaine MSDS

Mepivicaine Synthesis Reference

No information avaliable

Mepivicaine Molecular Weight

129.164 g/mol

Mepivicaine Melting Point

223-226 oC

Mepivicaine H2O Solubility

Freely soluble as HCl salt

Mepivicaine State


Mepivicaine LogP


Mepivicaine Dosage Forms

Extended release tablet (500 mg or 1000 mg)

Mepivicaine Indication

For use as an adjunct to diet and exercise to improve glycemic control in adult patients (18 years and older) with type 2 diabetes.

Mepivicaine Pharmacology

Metformin is an antihyperglycemic agent, which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and daylong plasma insulin response may actually decrease.

Mepivicaine Absorption

Absorbed over 6 hours, bioavailability is 50 to 60% under fasting conditions. Food delays absorption.

Mepivicaine side effects and Toxicity

Acute oral toxicity (LD50): 350 mg/kg [Rabbit]. It would be expected that adverse reactions of a more intense character including epigastric discomfort, nausea, and vomiting followed by diarrhea, drowsiness, weakness, dizziness, malaise and headache might be seen.

Mepivicaine Patient Information

Mepivicaine Organisms Affected

Humans and other mammals